Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$3.99 USD
+0.09 (2.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.98 -0.01 (-0.25%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Humacyte, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -110.78 | -11.97 | -26.48 | -0.23 | NA |
Depreciation/Amortization & Depletion | 8.20 | 9.76 | 9.22 | 0.00 | NA |
Net Change from Assets/Liabilities | 6.57 | 1.03 | -0.56 | 0.00 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 22.70 | -69.95 | -63.37 | -0.02 | NA |
Net Cash From Operating Activities | -73.31 | -71.13 | -81.19 | -0.25 | NA |
Property & Equipment | -2.28 | -1.05 | -0.22 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 2.11 | 5.89 | -8.00 | -100.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -0.17 | 4.85 | -8.22 | -100.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.57 | 0.54 | 0.60 | 101.58 | NA |
Issuance (Repayment) of Debt | 5.62 | -1.98 | 27.93 | 0.10 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -1.68 | 0.00 | 238.46 | -0.33 | NA |
Net Cash from Financing Activities | 4.51 | -1.45 | 266.98 | 101.34 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | -68.97 | -67.73 | 177.57 | 1.09 | NA |
Cash at Beginning of Period | 149.77 | 217.50 | 39.93 | 0.00 | NA |
Cash at End of Period | 80.80 | 149.77 | 217.50 | 1.09 | NA |
Diluted Net EPS | -1.07 | -0.12 | -0.66 | -0.08 | NA |
Fiscal Year End for Humacyte, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -110.78 | -85.67 | -59.68 | -36.97 |
Depreciation/Amortization & Depletion | NA | 8.20 | 6.37 | 4.54 | 2.43 |
Net Change from Assets/Liabilities | NA | 6.57 | 3.44 | -3.61 | -0.16 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 22.70 | 21.61 | 17.50 | 16.05 |
Net Cash From Operating Activities | NA | -73.31 | -54.25 | -41.24 | -18.64 |
Property & Equipment | NA | -2.28 | -2.13 | -1.64 | -1.15 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 2.11 | 2.11 | 2.11 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.17 | -0.02 | 0.47 | -1.15 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.57 | 0.31 | 0.21 | 0.12 |
Issuance (Repayment) of Debt | NA | 5.62 | 6.21 | 6.79 | -0.53 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -1.68 | -1.68 | -1.39 | 0.00 |
Net Cash from Financing Activities | NA | 4.51 | 4.84 | 5.61 | -0.41 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -68.97 | -49.43 | -35.17 | -20.20 |
Cash at Beginning of Period | NA | 149.77 | 149.77 | 149.77 | 149.77 |
Cash at End of Period | NA | 80.80 | 100.34 | 114.60 | 129.57 |
Diluted Net EPS | NA | -0.24 | -0.25 | -0.22 | -0.36 |